Glaxosmi. Pharma

Market Cap: Large Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE159A01016
NSEID: GLAXO
BSEID: 500660

INR

2,754.05

90.6 (3.4%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 57.76 k

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Laurus Labs

Divi's Lab.

Cipla

Ipca Labs

Glenmark Pharma

Sun Pharma.Inds.

Torrent Pharma

Glaxosmi. Pharma

Ajanta Pharma

Biocon

Mankind Pharma

Why is Glaxosmithkline Pharmaceuticals Ltd ?

Poor long term growth as Net Sales has grown by an annual rate of 2.97% and Operating profit at 12.47% over the last 5 years

Flat results in Dec 24

DEBTORS TURNOVER RATIO(HY) Lowest at 13.27 times

Stock is technically in a Mildly Bearish range

The technical trend has deteriorated from Sideways on 01-Apr-25 and has generated -1.06% returns since then
A key technical factor - RSI has been Bearish since 01 Apr 2025

With ROE of 46.9, it has a Very Expensive valuation with a 27 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 45.71%, its profits have risen by 37.1% ; the PEG ratio of the company is 1.4

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Glaxosmi. Pharma for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Glaxosmi. Pharma

45.33%

1.07

42.69%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

2.97%

EBIT Growth (5y)

12.47%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

2.01

Tax Ratio

26.69%

Dividend Payout Ratio

91.89%

Pledged Shares

Institutional Holding

11.81%

ROCE (avg)

-125.80%

ROE (avg)

54.93%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

26.97

EV to EBIT

41.72

EV to EBITDA

39.06

EV to Capital Employed

-101.63

EV to Sales

11.61

PEG Ratio

1.43

Dividend Yield

1.65%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

46.87%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

PAT(9M)

At Rs 661.27 cr has Grown at 33.06%

ROCE(HY)

Highest at 64.43%

-3What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 13.27 times

Loading Valuation Snapshot...

Here's what is working for Glaxosmi. Pharma

Profit After Tax (PAT) - Half Yearly

At Rs 478.94 cr has Grown at 26.92%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Glaxosmi. Pharma

Debtors Turnover Ratio- Half Yearly

Lowest at 13.27 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio